Wegovy is only approved for obesity in India. Novo Nordisk has no immediate plans to launch Ozempic for type 2 diabetes, though it is exploring oral semaglutide for obesity.

Novo Nordisk has officially launched its anti-obesity drug Wegovy in India ahead of patent expiry. This move aims to tackle rising obesity rates while facing competition from rival drugs.